WO2022017951A1 - Utilisation de cannabidiol dans le traitement de crises associées à des troubles liés au gène cask - Google Patents
Utilisation de cannabidiol dans le traitement de crises associées à des troubles liés au gène cask Download PDFInfo
- Publication number
- WO2022017951A1 WO2022017951A1 PCT/EP2021/069887 EP2021069887W WO2022017951A1 WO 2022017951 A1 WO2022017951 A1 WO 2022017951A1 EP 2021069887 W EP2021069887 W EP 2021069887W WO 2022017951 A1 WO2022017951 A1 WO 2022017951A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cbd
- preparation
- use according
- thc
- cannabinoids
- Prior art date
Links
- 229950011318 cannabidiol Drugs 0.000 title claims abstract description 129
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title claims abstract description 128
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title claims abstract description 127
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title claims abstract description 127
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title claims abstract description 127
- 206010010904 Convulsion Diseases 0.000 title claims abstract description 70
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 20
- 208000035475 disorder Diseases 0.000 claims abstract description 19
- 208000005392 Spasm Diseases 0.000 claims abstract description 13
- 208000007101 Muscle Cramp Diseases 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims description 54
- 229930003827 cannabinoid Natural products 0.000 claims description 45
- 239000003557 cannabinoid Substances 0.000 claims description 45
- 229940065144 cannabinoids Drugs 0.000 claims description 33
- 229960004242 dronabinol Drugs 0.000 claims description 27
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 20
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 20
- 239000001961 anticonvulsive agent Substances 0.000 claims description 14
- WBRXESQKGXYDOL-DLBZAZTESA-N 5-butyl-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol Chemical compound OC1=CC(CCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WBRXESQKGXYDOL-DLBZAZTESA-N 0.000 claims description 10
- 241000218236 Cannabis Species 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- CYQFCXCEBYINGO-SJORKVTESA-N (6as,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-SJORKVTESA-N 0.000 claims description 8
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims description 3
- 229960001403 clobazam Drugs 0.000 claims description 3
- 229960002623 lacosamide Drugs 0.000 claims description 3
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims description 3
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims description 3
- 229960005318 vigabatrin Drugs 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 abstract description 5
- 208000031977 Rare epilepsy Diseases 0.000 abstract description 4
- 206010015037 epilepsy Diseases 0.000 description 17
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 8
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 206010061334 Partial seizures Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940088679 drug related substance Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 4
- 235000008697 Cannabis sativa Nutrition 0.000 description 4
- 208000011038 Cold agglutinin disease Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229960003965 antiepileptics Drugs 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000020345 childhood apraxia of speech Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000014155 speech-language disorder-1 Diseases 0.000 description 4
- 208000002877 Epileptic Syndromes Diseases 0.000 description 3
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- 101150068312 CASK gene Proteins 0.000 description 2
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 2
- 201000007547 Dravet syndrome Diseases 0.000 description 2
- 208000024658 Epilepsy syndrome Diseases 0.000 description 2
- 206010021750 Infantile Spasms Diseases 0.000 description 2
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 2
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 2
- 244000010815 Phlomis lychnitis Species 0.000 description 2
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000004641 brain development Effects 0.000 description 2
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 208000005093 cerebellar hypoplasia Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- -1 e.g. Chemical compound 0.000 description 2
- 239000002621 endocannabinoid Substances 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 208000004141 microcephaly Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- 206010003628 Atonic seizures Diseases 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- 206010061991 Grimacing Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100031166 Peripheral plasma membrane protein CASK Human genes 0.000 description 1
- 101710112366 Peripheral plasma membrane protein CASK Proteins 0.000 description 1
- 206010034759 Petit mal epilepsy Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- 208000012471 X-linked intellectual disability Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001599 direct drying Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000537 electroencephalography Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 235000020887 ketogenic diet Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000031906 susceptibility to X-linked 2 autism Diseases 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Definitions
- the present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes.
- CBD cannabidiol
- the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with CAS -related disorders.
- the types of seizures include spasms.
- the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
- the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 95% of the total extract (w/w) and the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w).
- the CBD used is in the form of a botanically derived purified CBD which comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. More preferably the other cannabinoids present are THC at a concentration of less than or equal to 0.1% (w/w); CBD-C1 at a concentration of less than or equal to 0.15% (w/w); CBDV at a concentration of less than or equal to 0.8% (w/w); and CBD-C4 at a concentration of less than or equal to 0.4% (w/w).
- the botanically derived purified CBD preferably also comprises a mixture of both trans-THC and cis-THC. Alternatively, a synthetically produced CBD is used.
- the other cannabinoids present are THC at a concentration of about 0.01% to about 0.1% (w/w); CBD-C1 at a concentration of about 0.1% to about 0.15% (w/w); CBDV at a concentration of about 0.2% to about 0.8% (w/w); and CBD-C4 at a concentration of about 0.3% to about 0.4% (w/w).
- THC is present at a concentration of about 0.02% to about 0.05% (w/w).
- the CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form.
- Epilepsy occurs in approximately 1% of the population worldwide, (Thurman et al., 2011) of which 70% are able to adequately control their symptoms with the available existing anti-epileptic drugs (AED). However, 30% of this patient group, (Eadie et al., 2012), are unable to obtain seizure freedom from the AED that are available and as such are termed as suffering from intractable or “treatment-resistant epilepsy” (TRE).
- TRE treatment-resistant epilepsy
- Intractable or treatment-resistant epilepsy was defined in 2009 by the International League against Epilepsy (I LAE) as “failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom ” (Kwan et al., 2009).
- Childhood epilepsy is a relatively common neurological disorder in children and young adults with a prevalence of approximately 700 per 100,000. This is twice the number of epileptic adults per population.
- the main symptom of epilepsy is repeated seizures.
- Clinical observations and electroencephalography (EEG) tests are conducted and the type(s) of seizures are classified according to the ILEA classification.
- Generalized seizures where the seizure arises within and rapidly engages bilaterally distributed networks, can be split into six subtypes: tonic-clonic (grand mal) seizures; absence (petit mal) seizures; clonic seizures; tonic seizures; atonic seizures and myoclonic seizures.
- Focal (partial) seizures where the seizure originates within networks limited to only one hemisphere, are also split into sub-categories.
- the seizure is characterized according to one or more features of the seizure, including aura, motor, autonomic and awareness / responsiveness.
- a seizure begins as a localized seizure and rapidly evolves to be distributed within bilateral networks this seizure is known as a bilateral convulsive seizure, which is the proposed terminology to replace secondary generalized seizures (generalized seizures that have evolved from focal seizures and are no longer remain localized).
- focal seizures where the subject’s awareness / responsiveness is altered are referred to as focal seizures with impairment and focal seizures where the awareness or responsiveness of the subject is not impaired are referred to as focal seizures without impairment.
- CASK-related disorders are a group of genetic disorders that affect brain development. The two main related conditions are microcephaly with pontine and cerebellar hypoplasia and X-linked intellectual disability with or without nystagmus.
- CASK-related disorders are caused by mutations in the CASK gene and are inherited in an X-linked manner. Males with these disorders usually have more severe symptoms than females.
- CASK gene encodes calcium/calmodulin-dependent serine protein kinase (CASK) protein, which is found in neurons in the brain and is involved in regulating the activity of other genes involved in brain development and neurotransmitter movement.
- CASK calcium/calmodulin-dependent serine protein kinase
- Symptoms appear in infancy and typically progress over time. Symptoms include autism spectrum disorders, intellectual disability, epilepsy disorders, seizures, microcephaly with pontine and cerebellar hypoplasia, delayed growth, vision and hearing issues, and low muscle tone.
- Treatment is focused on alleviating symptoms and may include medication to control seizures, nutritional support, hearing and vision aids, and physical therapy.
- CBD Cannabidiol
- a cannabidiol (CBD) preparation for use in the treatment of seizures associated with CASK- related disorders.
- the seizures associated with CASK- related disorders are spasms.
- the CBD preparation comprises greater than 95% (w/w) CBD and not more than 0.15% (w/w) tetrahydrocannabinol (THC).
- the CBD preparation comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids, wherein the less than or equal to 2% (w/w) other cannabinoids comprise the cannabinoids tetrahydrocannabinol (THC); cannabidiol- C1 (CBD-C1); cannabidivarin (CBDV); and cannabidiol-C4 (CBD-C4), and wherein the THC is present as a mixture of trans-THC and cis-THC.
- THC cannabinoids tetrahydrocannabinol
- CBD-C1 cannabidiol- C1
- CBDDV cannabidivarin
- CBD-C4 cannabidiol-C4
- the CBD preparation is used in combination with one or more concomitant anti-epileptic drugs (AED).
- AED concomitant anti-epileptic drugs
- the one or more AED is selected from the group consisting of: clobazam, vigabatrin and lacosamide.
- the CBD is present is isolated from cannabis plant material.
- the CBD is present as a synthetic preparation.
- the dose of CBD is greater than 5 mg/kg/day. More preferably the dose of CBD is 20 mg/kg/day. More preferably the dose of CBD is 25 mg/kg/day. More preferably the dose of CBD is 50 mg/kg/day.
- a method of treating seizures associated with CAS -related disorders comprising administering a cannabidiol (CBD) preparation to the subject in need thereof.
- CBD cannabidiol
- cannabinoids Over 100 different cannabinoids have been identified, see for example, Handbook of Cannabis, Roger Pertwee, Chapter 1, pages 3 to 15. These cannabinoids can be split into different groups as follows: Phytocannabinoids; Endocannabinoids and Synthetic cannabinoids (which may be novel cannabinoids or synthetically produced phytocannabinoids or endocannabinoids). [0036] “Phytocannabinoids” are cannabinoids that originate from nature and can be found in the cannabis plant. The phytocannabinoids can be isolated from plants to produce a highly purified extract or can be reproduced synthetically.
- “Highly purified cannabinoids” are defined as cannabinoids that have been extracted from the cannabis plant and purified to the extent that other cannabinoids and non-cannabinoid components that are co-extracted with the cannabinoids have been removed, such that the highly purified cannabinoid is greater than or equal to 95% (w/w) pure.
- Synthetic cannabinoids are compounds that have a cannabinoid or cannabinoid-like structure and are manufactured using chemical means rather than by the plant.
- Phytocannabinoids can be obtained as either the neutral (decarboxylated form) or the carboxylic acid form depending on the method used to extract the cannabinoids. For example, it is known that heating the carboxylic acid form will cause most of the carboxylic acid form to decarboxylate into the neutral form.
- Treatment-resistant epilepsy (TRE) or “intractable epilepsy” is defined as per the I LAE guidance of 2009 as epilepsy that is not adequately controlled by trials of one or more AED.
- “Epileptic spasm”, “spasms”, “infantile spasm”, “juvenile spasm” or “West syndrome” is defined as sudden flexion, extension or mixed flexion-extension of proximal and truncal muscles, lasting 1-2 seconds. Spasms typically occur in a series, usually on wakening. Subtle forms may occur with only chin movement, grimacing, or head nodding. Spasms may be bilaterally symmetric, asymmetric, or unilateral, depending on whether they are generalised onset or focal onset.
- the drug substance used is a liquid carbon dioxide extract of high-CBD containing chemotypes of Cannabis sativa L. which had been further purified by a solvent crystallization method to yield CBD.
- the crystallisation process specifically removes other cannabinoids and plant components to yield greater than 95% CBD.
- CBD is highly purified because it is produced from a cannabis plant rather than synthetically there is a small number of other cannabinoids which are co-produced and co-extracted with the CBD. Details of these cannabinoids and the quantities in which they are present in the medication are as described in Table A below. Table A: Composition of highly purified CBD extract
- the drug substance used in the trials is a liquid carbon dioxide extract of high-CBD containing chemotypes of Cannabis sativa L. which had been further purified by a solvent crystallization method to yield CBD.
- the crystallisation process specifically removes other cannabinoids and plant components to yield greater than 95% CBD w/w, typically greater than 98% w/w.
- the Cannabis sativa L. plants are grown, harvested, and processed to produce a botanical extract (intermediate) and then purified by crystallization to yield the CBD (botanically derived purified CBD).
- the plant starting material is referred to as Botanical Raw Material (BRM); the botanical extract is the intermediate; and the active pharmaceutical ingredient (API) is CBD, the drug substance.
- BRM Botanical Raw Material
- API active pharmaceutical ingredient
- Table B CBD botanical raw material specification
- the purity of the botanically derived purified CBD preparation was greater than or equal to 98%.
- the botanically derived purified CBD includes THC and other cannabinoids, e.g., CBDA, CBDV, CBD-C1, and CBD-C4.
- the CBD preparation comprises not more than 0.15% THC based on total amount of cannabinoid in the preparation. In some embodiments, the CBD preparation comprises about 0.01% to about 0.1% THC based on total amount of cannabinoid in the preparation. In some embodiments, the CBD preparation comprises about 0.02% to about 0.05% THC based on total amount of cannabinoid in the preparation.
- the CBD preparation comprises about 0.2% to about 1.0% CBDV based on total amount of cannabinoid in the preparation. In some embodiments, the CBD preparation comprises about 0.2% to about 0.8% CBDV based on total amount of cannabinoid in the preparation. [0052] In some embodiments, the CBD preparation comprises about 0.3% to about 0.5%
- CBD-C4 based on total amount of cannabinoid in the preparation.
- the CBD preparation comprises about 0.3% to about 0.4% CBD-C4 based on total amount of cannabinoid in the preparation.
- the CBD preparation comprises about 0.1% to about 0.15% CBD-C1 based on total amount of cannabinoid in the preparation.
- Distinct chemotypes of the Cannabis sativa L. plant have been produced to maximize the output of the specific chemical constituents, the cannabinoids. Certain chemovars produce predominantly CBD. Only the (-)-trans isomer of CBD is believed to occur naturally. During purification, the stereochemistry of CBD is not affected.
- High CBD chemovars were grown, harvested, dried, baled and stored in a dry room until required.
- the botanical raw material (BRM) was finely chopped using an Apex mill fitted with a 1 mm screen. The milled BRM was stored in a freezer prior to extraction.
- the BDS produced using the methodology above was dispersed in C5-C12 straight chain or branched alkane.
- the mixture was manually agitated to break up any lumps and the sealed container then placed in a freezer for approximately 48 hours.
- the crystals were isolated via vacuum filtration, washed with aliquots of cold C5-C12 straight chain or branched alkane, and dried under a vacuum of ⁇ 10mb at a temperature of 60°C until dry.
- the botanically derived purified CBD preparation was stored in a freezer at -20°C in a pharmaceutical grade stainless steel container, with FDA food grade approved silicone seal and clamps.
- the botanically derived purified CBD used in the clinical trial described in the invention comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids.
- the other cannabinoids present are THC at a concentration of less than or equal to 0.1% (w/w); CBD-C1 at a concentration of less than or equal to 0.15% (w/w); CBDV at a concentration of less than or equal to 0.8% (w/w); and CBD-C4 at a concentration of less than or equal to 0.4% (w/w).
- the botanically derived purified CBD used additionally comprises a mixture of both trans-THC and cis-THC. It was found that the ratio of the trans-THC to cis-THC is altered and can be controlled by the processing and purification process, ranging from 3.3:1 (trans-THC:cis- THC) in its unrefined decarboxylated state to 0.8:1 (trans-THC:cis-THC) when highly purified. [0063] Furthermore, the cis-THC found in botanically derived purified CBD is present as a mixture of both the (+)-cis-THC and the (-)-cis-THC isoforms.
- CBD preparation could be produced synthetically by producing a composition with duplicate components.
- Example 1 describes the use of a botanically derived purified CBD in an open label, expanded-access program to investigate the clinical efficacy and safety of purified pharmaceutical cannabidiol formulation (CBD) in the treatment of CAS -related disorders.
- CBD cannabidiol formulation
- EXAMPLE 1 CLINICAL EFFICACY AND SAFETY OF PURIFIED PHARMACEUTICAL CANNABIDIOL (CBD) IN THE TREATMENT OF PATIENTS DIAGNOSED WITH CASK- RELATED DISORDERS
- VNS vagus nerve stimulation
- the patient was administered botanically derived purified CBD in a 100 mg/ml_ sesame oil-based solution at an initial dose of 15 milligrams per kilogram per day (mg/kg/day) in two divided doses. Dose was then increased weekly by 5mg/kg/day to a goal of 25 mg/kg/day.
- a maximum dose of 50 mg/kg/day could be utilised for the patient if they were tolerating the medication but had not achieved seizure control; the patient had further weekly titration by 5mg/kg/day.
- Seizure frequency, intensity, and duration were recorded by caregivers in a diary during a baseline period of at least 28 days. Changes in seizure frequency relative to baseline were calculated after at least 2 weeks and at defined timepoints of treatment.
- Patients may be defined as responders if they had more than 50% reduction in seizure frequency compared to baseline.
- the percent change in seizure frequency was calculated as follows:
- % change ((weekly seizure frequency time interval)- (weekly seizure frequency Baseline)) x100 seizure (weekly seizure frequency Baseline) frequency
- the percent change of seizure frequency may be calculated for any time interval where seizure number has been recorded.
- the percent change of seizure frequency for the end of the treatment period was calculated as follows:
- % reduction ((weekly seizure frequency Baseline) - (weekly seizure frequency End)) x100 seizure frequency (weekly seizure frequency Baseline)
- Patient description [0073] One patient enrolled in the open label, expanded-access program was diagnosed with CAS -related disorder. The patient experienced spasms and was taking several concomitant AEDs.
- Table 1 Patient demographics, seizure type and concomitant medication
- CLB clobazam
- VGB vigabatrin
- LCS lacosamide Study medication and concomitant medications
- the patient on the study was titrated up to 25 mg/kg/day of CBD.
- the patient was on three concomitant AEDs at the time of starting CBD.
- Table 2 illustrates the seizure frequency for the patient as well as the dose of CBD given.
- Patient 1 was treated for 132 weeks and experienced a 100% reduction in spasms over the treatment period.
- this study signifies the use of CBD for treatment of seizures associated with CASK-related disorders.
- Seizure types include spasms for which seizure frequency rates decreased significantly, by 100%.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne l'utilisation de cannabidiol (CBD) pour le traitement de crises associées à des syndromes épileptiques rares. En particulier, les crises associées à des syndromes épileptiques rares qui sont traitées sont celles survenant chez des patients chez lesquels on a diagnostiqué des troubles liés au gène CASK. Dans un autre mode de réalisation, les types de crises comprennent des spasmes. De préférence, la dose de CBD est comprise entre 5 mg/kg/jour et 50 mg/kg/jour.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2011163.9A GB2597314A (en) | 2020-07-20 | 2020-07-20 | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2011163.9 | 2020-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022017951A1 true WO2022017951A1 (fr) | 2022-01-27 |
Family
ID=72338988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/069887 WO2022017951A1 (fr) | 2020-07-20 | 2021-07-15 | Utilisation de cannabidiol dans le traitement de crises associées à des troubles liés au gène cask |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2597314A (fr) |
WO (1) | WO2022017951A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190091174A1 (en) | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Method of reducing seizure type experienced by a dravet patient |
US20190247333A1 (en) | 2017-09-26 | 2019-08-15 | Zogenix International Limited | Method of reduction in convulsive seizure frequency |
WO2019207319A1 (fr) * | 2018-04-27 | 2019-10-31 | GW Research Limited | Préparations de cannabidiol et leurs utilisations |
WO2020112460A1 (fr) | 2018-11-30 | 2020-06-04 | Zogenix International Limited | Procédé de traitement de syndromes d'épilepsie réfractaire à l'aide d'énantiomères de fenfluramine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202104378SA (en) * | 2018-11-19 | 2021-05-28 | Zogenix International Ltd | Methods of treating rett syndrome using fenfluramine |
-
2020
- 2020-07-20 GB GB2011163.9A patent/GB2597314A/en active Pending
-
2021
- 2021-07-15 WO PCT/EP2021/069887 patent/WO2022017951A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190091174A1 (en) | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Method of reducing seizure type experienced by a dravet patient |
US20190247333A1 (en) | 2017-09-26 | 2019-08-15 | Zogenix International Limited | Method of reduction in convulsive seizure frequency |
WO2019207319A1 (fr) * | 2018-04-27 | 2019-10-31 | GW Research Limited | Préparations de cannabidiol et leurs utilisations |
WO2020112460A1 (fr) | 2018-11-30 | 2020-06-04 | Zogenix International Limited | Procédé de traitement de syndromes d'épilepsie réfractaire à l'aide d'énantiomères de fenfluramine |
Non-Patent Citations (5)
Title |
---|
BALESTRINI S ET AL: "Treatment of epileptic encephalopathies", vol. 23, no. 37, 1 October 2017 (2017-10-01), pages 5667 - 5690, XP009530524, ISSN: 1381-6128, Retrieved from the Internet <URL:http://www.eurekaselect.com/154786/article> DOI: 10.2174/1381612823666170809115827 * |
HERLOPIAN ALINE ET AL: "Cannabidiol in treatment of refractory epileptic spasms: An open-label study", EPILEPSY AND BEHAVIOR, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 106, 10 March 2020 (2020-03-10), XP086148260, ISSN: 1525-5050, [retrieved on 20200310], DOI: 10.1016/J.YEBEH.2020.106988 * |
HUSSAIN SHAUN A ET AL: "Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut synd", EPILEPSY AND BEHAVIOR, vol. 47, 29 April 2015 (2015-04-29), pages 138 - 141, XP029215861, ISSN: 1525-5050, DOI: 10.1016/J.YEBEH.2015.04.009 * |
ROGER PERTWEE: "Handbook of Cannabis", pages: 3 - 15 |
UTE MOOG ET AL: "Phenotypic and molecular insights into CASK-related disorders in males", ORPHANET JOURNAL OF RARE DISEASES, BIOMED CENTRAL LTD, LO, vol. 10, no. 1, 12 April 2015 (2015-04-12), pages 44, XP021223245, ISSN: 1750-1172, DOI: 10.1186/S13023-015-0256-3 * |
Also Published As
Publication number | Publication date |
---|---|
GB202011163D0 (en) | 2020-09-02 |
GB2597314A (en) | 2022-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020279889A1 (en) | Use of cannabidiol in the treatment of epileptic spasms | |
EP4181902A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques | |
WO2022017942A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à des mutations dans le gène syngap1 | |
EP4181896A1 (fr) | Cannabidiol destiné à être utilisé dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques | |
EP4181894A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques | |
EP4181899A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques | |
WO2022017945A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques | |
WO2022017949A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à une mutation de chrna4 | |
EP4181895A1 (fr) | Utilisation du cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques | |
WO2022017951A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à des troubles liés au gène cask | |
WO2022017925A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées au syndrome épileptique multifocal | |
WO2022017943A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à une déficience en arginase | |
WO2022017955A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies structurales du cerveau | |
WO2022017954A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies structurales du cerveau | |
GB2597285A (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities | |
WO2022017934A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées au syndrome de rubinstein-taybi | |
WO2022017917A1 (fr) | Cannabidiol destiné à être utilisé dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies structurales du cerveau | |
WO2022017944A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à une dégénérescence cérébrale bilatérale | |
EP4181889A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à des syndromes rares d'épilepsie liés à des anomalies génétiques | |
EP4181898A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques | |
WO2022017927A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées au syndrome de fissure périsylvienne | |
WO2022017913A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques | |
WO2022017961A1 (fr) | Utilisation du cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques | |
WO2022017953A1 (fr) | Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques | |
GB2597306A (en) | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21751749 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21751749 Country of ref document: EP Kind code of ref document: A1 |